Pulmonary Arterial Hypertension: Best Practice for Diagnosis and Management

Pulmonary hypertension (PH) is a progressive disease that continues to have poor 5-year survival rates. Pulmonary arterial hypertension (PAH) is one of 5 subtypes of PH. Because PAH is rare and the signs and symptoms nonspecific, clinicians often do not consider it in the differential diagnosis. When the diagnosis is considered, patients may not undergo all required testing for diagnostic accuracy and for many the diagnosis is delayed 3 or 4 years.

Determination of risk is key to selecting the appropriate therapy for patients with PAH, and evidence-based guidance for establishing level of risk has been published. Clinicians have several classes of agents to choose from when developing a management strategy for PAH. The patient’s experience and treatment goals should also be considered.

“Pulmonary Arterial Hypertension: Best Practice for Diagnosis and Management” will provide clinicians with information about diagnostic criteria and evidence-based management of patients with PAH.

Jointly provided by the Potomac Center for Medical Education and Rockpointe

Click here for the Rockpointe Privacy Policy

Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.